Last updated: May 25, 2026
Dorzolamide Hydrochloride Suppliers: Active Ingredient, APIs, and Formulation Manufacturers
Dorzolamide hydrochloride is supplied globally in multiple forms for ophthalmic products, with most market supply anchored in generic ophthalmic formulation manufacturers. Upstream API supply typically runs through bulk chemical producers in China/India, while finished-dose ophthalmic products are produced by regional formulation specialists and contract manufacturers for brands and private-label generics.
Bottom line for sourcing: the supplier landscape splits into (1) API and intermediates and (2) ophthalmic finished-dose manufacturers (often sterile ophthalmic liquids), where regulatory dossiers and DMF/CEP status drive shortlist inclusion.
Who supplies dorzolamide hydrochloride API and intermediates?
Typical supplier types
- API manufacturers producing dorzolamide hydrochloride bulk drug substance.
- Intermediate producers feeding dorzolamide API synthesis (more common than full transparency suggests in public procurement).
- Importer-distributors that repackage API from one or more upstream plants into local supply chains.
Common sourcing geographies (market pattern)
- China: largest concentration of small-molecule API capacity for ophthalmics and related carbonic anhydrase inhibitors.
- India: active in generic ophthalmic APIs and intermediates.
- Europe and Japan: lower share for API sourcing, higher share for finished-dose brands, licensing, and regulatory oversight.
What buyers screen for when qualifying API
- Quality system (GMP compliance and audit readiness).
- Drug substance impurity profile matching existing regulatory filings.
- DMF coverage (US) or CEP (Europe) status for faster regulatory pathway.
- Sterile ophthalmic compatibility via controlled solvent residues and particle specs.
- Supply continuity for ophthalmic seasonality and wholesaler fill rates.
What API specifications and compliance issues matter for ophthalmics?
Key qualification drivers for dorzolamide hydrochloride API used in ophthalmic solutions include:
- Particle size and reactivity profile for consistent solubilization at low-dose concentrations.
- Control of specified impurities that can shift pH stability and shelf-life in aqueous buffered systems.
- Consistency of monograph and internal testing across lots (assay, water content, related substances).
Which companies manufacture finished-dose dorzolamide hydrochloride ophthalmic products?
Finished-dose supply for dorzolamide hydrochloride is concentrated among generic ophthalmic leaders and sterile contract manufacturers that can handle:
- Sterile manufacturing of ophthalmic liquids
- Container closure systems (commonly multi-dose or unit-dose)
- Preservative systems (where applicable) and pH/buffering optimization
- Batch release testing aligned with ophthalmic sterility and particle specs
Is dorzolamide usually sold as monotherapy or fixed combinations?
Most commercial activity involves either:
- Dorzolamide hydrochloride ophthalmic solution (monotherapy), and
- Fixed combinations with timolol (commonly marketed as dorzolamide/timolol ophthalmic solutions in multiple strengths).
This matters for supplier strategy because combination products require compatibility across two APIs and a single sterile formulation platform.
What patent and regulatory factors affect supplier eligibility for dorzolamide products?
Supplier qualification is often shaped less by API patenting and more by:
- Regulatory exclusivity and reference product status for specific formulations
- ANDA submission structure (including any listed patents)
- Whether a product can rely on a listed right-of-reference in an associated application history
How does FDA Orange Book status influence new supplier launches?
For US ophthalmics, Orange Book listings can constrain:
- ANDA timing (whether an applicant can file and when it can market)
- Paragraph IV risk for brands’ listed patents
- Settlement-triggered launch windows that delay generic competition for specific presentation strengths and container formats
How do fixed-dose combination products change the supplier landscape?
For dorzolamide plus timolol combinations, supplier qualification depends on:
- Availability of both APIs through approved pathways
- Sterile formulation capability for a two-API system
- Proven compatibility with preservatives and buffer systems used in timolol ophthalmics
Which risk is higher for combination products: API or sterile formulation?
Usually the limiting factor is sterile ophthalmic manufacturing and formulation stability, not just API availability. A supplier can often source dorzolamide API, but pairing with timolol and meeting shelf-life and particle/sterility criteria is harder.
Which manufacturing models are used for ophthalmic dorzolamide supply?
The supplier ecosystem generally uses three models:
- Vertically integrated finished-dose manufacturers with internal sterile lines.
- Contract manufacturing organizations (CMOs) producing sterile ophthalmic liquids for multiple brand labels.
- License-based manufacturing where a local firm manufactures under regulatory and technical transfer controls.
What procurement documents determine supplier fit?
- CoA/CoC and audit reports
- DMF/CEP registration evidence (where applicable)
- Analytical method transfer readiness
- Packaging and labeling compliance plans for target markets
What generic entry risks exist for dorzolamide hydrochloride products?
Generic entry for dorzolamide typically faces:
- Listed-patent risk for specific strengths/presentations
- In-market product switching barriers (pharmacy stocking and payer preferences)
- Bioequivalence and formulation acceptance in the ANDA pathway
- Ophthalmic-specific quality constraints (sterility, viscosity, pH, preservative performance)
Paragraph IV and litigation risk
If an ANDA targets a product with listed patents, the applicant can face:
- Infringement claims
- Possible 30-month stay of approval (depending on trigger)
- Settlement agreements that move launch timing
This affects supplier strategy because it impacts when API and bulk packaging volumes translate into revenue.
What is the typical worldwide commercial supplier pattern for dorzolamide?
Market pattern
- Multiple independent API plants supply a small number of large ophthalmic formulation manufacturers.
- Finished-dose availability is often broader across countries than API availability because formulation suppliers can contract for API and manage DMF/quality expectations.
Procurement implication
- Buyers should qualify at both levels: upstream API and sterile finished-dose capabilities for packaging configuration.
Key Takeaways
- Dorzolamide hydrochloride sourcing splits into API/intermediate suppliers and sterile ophthalmic finished-dose manufacturers.
- The practical supplier shortlist for business use typically depends on DMF/CEP status, impurity control, and sterile ophthalmic manufacturing capability.
- For combination products, formulation and sterile compatibility (with timolol) is usually the gating factor, not only API supply.
- In the US, Orange Book-listed patents and ANDA strategy can drive launch timing and supplier procurement volumes.
FAQs
1) Who can supply dorzolamide hydrochloride API for US ANDAs?
API suppliers must support the dossier path required for the specific ANDA (DMF linkage and impurity controls are decisive).
2) Are dorzolamide ophthalmic products sourced mostly from China or India?
API capacity is heavily concentrated in Asia, while finished-dose supply often involves both Asian and global ophthalmic formulation specialists.
3) Do combination products like dorzolamide/timolol require different supplier qualification?
Yes. Qualification expands from dorzolamide API to two-API sterile formulation capability and stability in a single ocular solution.
4) What are the main quality risks for ophthalmic dorzolamide liquids?
Sterility assurance, particle/viscosity control, buffer/pH stability, and preservative performance.
5) What drives supplier selection for ophthalmic containers and packaging?
Container closure compatibility, extractables/leachables controls, and labeling configurations tied to target-market requirements.
References
No sources were cited because no supplier name list, regulatory dossier identifiers (DMF/CEP), FDA/Orange Book entries, or procurement records were provided in the prompt.
